DOTBIO PTE. LTD.
DotBio is focused on the development of novel immuno-oncology drugs based on humanized domain antibodies, its proprietary DotBody technology. DotBodies are domain therapeutic antibodies which are multi-specific, humanized and highly-stable. The company was founded by Professor Pär Nordlund and Dr. Ignacio Asial, who de
DOTBIO PTE. LTD. operates in biotech based in Singapore, founded in 2017.
Profile
DotBio is focused on the development of novel immuno-oncology drugs based on humanized domain antibodies, its proprietary DotBody technology. DotBodies are domain therapeutic antibodies which are multi-specific, humanized and highly-stable. The company was founded by Professor Pär Nordlund and Dr. Ignacio Asial, who designed and conceptualized the DotBody technology based on their expertise in protein and antibody engineering at Singapore’s Nanyang Technological University.
The company sits in the biotech segment, where it competes on its core product or service.
The business is associated with Singapore.
Its current recorded stage is Startup SG directory startup.
The company reports a headcount in the 1 - 10 range.
| Sector | Biotech |
|---|---|
| Country | Singapore |
| Founded | 2017 |
| Employees | 1 - 10 |
| Stage | Startup SG directory startup |
Website: www.dotbiopharma.com
Create a free account